Drug Targets for Liver Cancer

Drug Targets for Liver Cancer

Drug targets for Liver cancer: pharmacology information

Drug targets for Liver cancer: bioreagents

Drug Targets PDGFR for Liver Cancer with Approved Drugs

Drug targets Cancer drugs Company
PDGFR-α Sorafenib Bayer and Onyx Pharmaceuticals
PDGFR-β Sorafenib Bayer and Onyx Pharmaceuticals

The development of tyrosine kinase inhibitors (TKIs) has been an important avenue for the research of new treatments for advanced Liver disease. Many of the most successful inhibitors to date have cotargeted the components of the platelet-derived growth factor (PDGF) family of ligands and their receptors. While the β isoform of this receptor, platelet-derived growth factor receptor β (PDGFRβ), has been at the forefront of PDGF signaling in the Liver due to its important roles in nonparenchymal cells (NPCs), especially myofibroblast activation during fibrosis, several new studies have shown an emerging role of platelet-derived growth factor receptor α (PDGFRα) in Liver pathophysiology that may identify this receptor as an important therapeutic target. These findings suggest that unregulated PDGFRα signaling is pathogenic and may promote hepatocarcinogenesis. The number of studies suggesting a role of PDGFRα in promoting hepatocarcinogenesis has been a driving impetus for the further study of specific roles of PDGFRα in Liver cancer. (Kikuchi A, Monga SP. PDGFRα in Liver Pathophysiology: Emerging Roles in Development, Regeneration, Fibrosis, and Cancer. Gene expression. 2015;16(3):109-127.)

Drug targets for Liver cancer: Related Information